Charles Johannes
Founder, President & Chief Scientist EPOC Scientific
Dr. Charlie Johannes is Founder, President, and Chief Scientist at EPOC Scientific and Co-Founder, Board of directors, Vice President and Executive Editor of the Peptide Drug Hunting Chronicle for the Peptide Drug Hunting Consortium (PDHC). He previously served as Vice President of Exploratory Chemistry at Fog Pharmaceuticals (formerly Parabilis Medicines), where he led the development of hyper-stabilized helical peptides known as Helicons™. With 27 years of industry experience across Eisai, Infinity, Forma, A*STAR, and Fog, Charlie now advises startups, biotechnology companies, and venture firms on platform technologies, drug discovery across multiple modalities including small molecules, macrocycles, degraders, and peptide therapeutics, and translational strategy. He is recognized as an innovation champion, skilled in building discovery platforms, advancing novel modalities, and leading agile interdisciplinary teams across pharmaceutical, biotechnology, and national research organizations. Charlie earned his Ph.D. in Organic Chemistry from Boston College under Professor Amir Hoveyda.
Seminars
This your chance to hear from pioneering executive leaders the peptide space who will discuss their ambitions, strategies and challenges for peptide discovery, targets. indications and development of next generation of peptide drugs.
Key questions to be addressed include:
- What are the future opportunities, promising targets and applications on the horizon for peptide-drugs to achieve the next best in-market approval?
- Where is the next big wave heading after GLP-1 peptides?
- How will peptide-drugs compete against the biologics, antibody and small molecule markets as standards of care?
The biopharmaceutical sector continues to innovate peptide discovery innovations, from new macrocycles to new delivery methods and are thriving on strategic alliances, which allow for cross-functional sharing of knowledge, and experience to advance peptide drugs to patients faster. Hear first-hand how investors and key biotechs are keeping up with the peptide momentum through investments, alliances and collaborations.
Key questions to be addressed include:
- How to strategize the complexities, risks and decision-making strategies for choosing the right platform to invest and advance innovative approaches in the peptide industry?
- What are the key areas and spaces that peptides can fill in the biotechnology sector?
- What does it take for a small biotech to survive and get noticed from an investor or big pharma?
